Catalio Capital Management invests in Evvy

Deal terms as reported in the coverage below.

Decision brief

What changed

Evvy (Allora Health Inc.) raised a $40 million Series B led by Catalio Capital Management, with participation from several other investors. According to the reported coverage, Evvy will use the funding to scale and validate its AI-enabled diagnostics and care platform, beginning with fertility-focused care.

Why it matters

This financing signals continued investor support for AI-driven precision diagnostics in women’s health, especially where better diagnosis and lower recurrence rates could support differentiated care models. For decision-makers in healthcare, diagnostics, and digital health, the event matters because fresh capital can accelerate product validation, category competition, and partnership activity around fertility and related women’s health services.

Affected roles

CEO CTO CMO

Evidence

The coverage comes from a single SiliconANGLE AI article reporting the $40 million Series B, the investor list, and Evvy’s stated plans for the capital. The same article attributes performance claims—such as diagnosing more than 90% of symptomatic patients and reducing recurrence of bacterial vaginosis by 50%—to the company rather than to independent validation.

What remains uncertain

Open questions include how broadly Evvy’s reported outcomes generalize across patient populations, care settings, and conditions beyond the examples cited. The coverage does not provide independent clinical validation details, commercial traction metrics, regulatory status, or timelines for the fertility-focused expansion, so assumptions about near-term market impact remain unverified.

Monitor next

Watch for independent clinical validation results or commercial rollout details for Evvy’s fertility-focused AI diagnostic and care offerings.

Analytical support, not advice — assumptions and open questions stated above.

Source coverage